false
Catalog
Making Sense of the Expanding Molecular Toolbox fo ...
Advances in Diagnostic and Prognostic Testing in C ...
Advances in Diagnostic and Prognostic Testing in Cutaneous Melanoma
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Aaron Farberg, a dermatologist based in Dallas, Texas, discussed advances in diagnostic and prognostic testing for cutaneous melanoma in a detailed presentation. He focused on gene expression profiling (GEP) technologies, specifically the 23-GEP and 31-GEP tests, which aim to improve the accuracy of melanoma diagnosis and prognosis.<br /><br />Dr. Farberg highlighted the challenges in accurately diagnosing melanoma and emphasized the importance of identifying the malignant potential of ambiguous lesions. He explained how GEP technologies analyze gene expression to provide more definitive diagnoses and improve patient outcomes.<br /><br />The presentation included studies demonstrating the effectiveness of GEP testing in stratifying patients and guiding clinical decision-making. Dr. Farberg also discussed the impact of GEP testing on patient management, such as recommending routine imaging for high-risk patients identified by the 31-GEP test.<br /><br />Overall, the presentation underscored the role of GEP technologies in precision medicine for melanoma patients, offering insights into improved outcomes and patient satisfaction with the testing process.
Asset Subtitle
Aaron S. Farberg, MD, FAAD
Keywords
Dr. Aaron Farberg
dermatologist
Dallas, Texas
cutaneous melanoma
gene expression profiling
23-GEP test
31-GEP test
Legal notice
Copyright © 2025 American Academy of Dermatology. All rights reserved.
Reproduction or republication strictly prohibited without prior written permission.
×
Please select your language
1
English